ProMedix
Private Company
Funding information not available
Overview
ProMedix is a private, clinical-stage diagnostics company developing the PeriFRL, a noninvasive, Bluetooth-connected monitor that digitizes the measurement of capillary refill time (CRT) to assess peripheral perfusion. The technology addresses the unreliability of subjective CRT assessment and targets critical conditions like sepsis, shock, and hemorrhage, with initial validation from over 2,000 patient encounters under IRB protocols. Backed by industrial and institutional partners, the company is positioning its affordable, easy-to-use device for use in hospitals, home health, and pre-hospital settings, aligning with clinical guidelines that recommend CRT for resuscitation guidance.
Technology Platform
Digital capillary refill time (CRT) sensor platform consisting of a noninvasive hardware device connected via Bluetooth to a mobile application. The platform uses optical sensing and proprietary algorithms to provide an objective, quantitative measurement of peripheral blood flow reperfusion time.
Opportunities
Risk Factors
Competitive Landscape
ProMedix's direct competition is the current standard of care: the subjective, manual capillary refill test performed by clinicians. Indirect competitors include other noninvasive perfusion monitoring technologies like laser Doppler, tissue oxygenation sensors, and advanced vital signs monitors, though these are often more complex and expensive. ProMedix's niche is specifically digitizing and simplifying the CRT measurement.